SCHEMBL6979127

SCHEMBL6979127

CC(C)c1nc2ccc(F)c(F)c2[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.41
HSD17B10 Q99714 2/20 0.41
LMNA P02545 1/20 0.41
ADORA3 P0DMS8 2/20 0.36
ADORA2A P29274 2/20 0.36
ADORA1 P30542 2/20 0.36
ADORA2B P29275 1/20 0.36
NOS1 P29475 3/20 0.34
NOS2 P35228 3/20 0.34
NOS3 P29474 2/20 0.34
ALDH1A1 P00352 2/20 0.33
ALPL P05186 1/20 0.33
ALPI P09923 1/20 0.33
ALPG P10696 1/20 0.33
HPGD P15428 1/20 0.33
CYP1A2 P05177 1/20 0.33
SCN10A Q9Y5Y9 1/20 0.32
AR P10275 1/20 0.31
GSK3B P49841 1/20 0.31
ALOX15 P16050 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24312996 0.86 KDM4E (0.41) KDM4EHSD17B10LMNAADORA3ADORA2A
SCHEMBL22962142 0.84 KDM4E (0.40) KDM4EHSD17B10LMNAADORA3ADORA2A
SCHEMBL24313051 0.84 EIF4A3 (0.44) KDM4EHSD17B10LMNAADORA3ADORA2A
SCHEMBL6985646 0.83 SCN10A (0.37) NOS1NOS2NOS3ALDH1A1ALPL
SCHEMBL15042816 0.82 KDM4E (0.50) KDM4EHSD17B10LMNAADORA3ADORA2A
SCHEMBL12309239 0.79 KDM4E (0.45) KDM4EHSD17B10LMNAADORA3ADORA2A
SCHEMBL431611 0.76 ALDH1A1 (0.43) KDM4EHSD17B10LMNAADORA3ALDH1A1
SCHEMBL11874941 0.75 AR (0.35) AR
SCHEMBL22962073 0.74 ADORA3 (0.37) KDM4EHSD17B10LMNAADORA3ADORA2A
SCHEMBL13453668 0.73 KDM4E (0.44) KDM4EHSD17B10LMNAADORA3ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3752498-B1 SOMATOSTATIN MODULATORS AND USES THEREOF CRINETICS PHARMACEUTICALS INC (US) 2023-06-28 EP disclosed
US-11072598-B2 Somatostatin modulators and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2021-07-27 US disclosed
US-20210040087-A1 SOMATOSTATIN MODULATORS AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-02-11 US disclosed
US-8183276-B2 Therapeutic agents MERCK SHARP & DOHME CORP. 2012-05-22 US disclosed
US-8017605-B2 P38 kinase inhibiting agents MERCK SHARP & DOHME CORP. (US) 2011-09-13 US disclosed
US-20100324029-A1 THERAPEUTIC AGENTS MERCK SHARP & DOHME CORP. 2010-12-23 US disclosed
US-20090325953-A1 P38 KINASE INHIBITING AGENTS MERCK SHARP & DOHME LLC 2009-12-31 US disclosed
WO-2008097538-A1 THERAPEUTIC AGENTS MERCK & CO., INC. (US) 2008-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325953-A1 P38 KINASE INHIBITING AGENTS MAPK1, MAPK8, MAPKAPK2 KDM4E 4664/4885HSD17B10 3463/4885LMNA 4201/4885
US-20210040087-A1 SOMATOSTATIN MODULATORS AND USES THEREOF SSTR5, SSTR2, SSTR4 KDM4E 4554/4885HSD17B10 3787/4885LMNA 3475/4885
US-20100324029-A1 THERAPEUTIC AGENTS PSEN2, PSEN1, BACE2 KDM4E 3970/4885HSD17B10 1886/4885LMNA 1357/4885
US-11072598-B2 Somatostatin modulators and uses thereof SSTR5, SSTR2, SSTR4 KDM4E 4554/4885HSD17B10 3787/4885LMNA 3475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.